with an
Acco share
you get a discount on Acco-titles, office supplies and selected titles.
Content
Unlike other books on IBD which focus on systematic diagnosis, treatment plans, etc., this book addresses the key dilemmas that specialists face every day, providing a clinically focused analysis of controversial areas of IBD management, including emerging treatment therapies, surgical issues, and infection. Fully 75% of the book covers brand-new dilemmas, with the remaining 25% fully revised to incorporate the latest clinical thinking. Each chapter contains a learning points box to give clear take-home messages. Peter Irving MD MRCP (Editor), Corey A. Siegel MD MS (Editor), David Rampton DPhil FRCP (Editor), Fergus Shanahan MD (Editor) Table of Contents List of Contributors. Preface. Part 1: Genes and Phenotype in IBD. 1 Which will take us further in IBD - study of coding variation or epigenetics? (Miles Parkes). 2 IBD in different ethnic groups: same or different? (Rupert W.L. Leong, Dorothy K.L. Chow and Christian P. Selinger). Part 2: Bugs and IBD - good, bad or indifferent? 3 How does the risk of infection influence management of IBD around the world? (Kiran K. Peddi and Ian Craig Lawrance). 4 Travelling with IBD (Ing Shian Soon and Gilaad Kaplan). 5 What to do about hepatitis B and hepatitis C in patients with IBD (Morven Cunningham and Graham R. Foster). 6 CMV in IBD - passenger or pathogen? (Ahmed Kandiel & Bret Lashner). 7 Clostridium difficile in IBD: Impact, Prevention and Treatment (Ashwin N. Ananthakrishnan and David G. Binion). 8 Pre- and synbiotics: placebo or panacea (James O. Lindsay). 9 Worms - light at the end of their burrow? (John Leung and Joel V. Weinstock). 10 Do we really need to vaccinate all patients with IBD? (Gauree Gupta and Gil Y. Melmed). Part 3: Investigating IBD. 11 Biomarkers in IBD: myth or marvel? (Richard B. Gearry, Andrew S. Day). 12 Radiation exposure in IBD: how do we minimize the dangers? (Owen J O'Connor, Alan N. Desmond, Fergus Shanahan and Michael M. Maher). 13 Surveillance colonoscopy in UC - what's the best way to do it? (Matt Rutter). Part 4: Medical therapy. 5-ASA. 14 New 5ASAs: a tiny step or giant stride forward? (L. Campbell Levy). 15 Do 5ASAs prevent cancer? (Richard Logan and Venkataraman Subramanian). 16 Why do we still use 5-ASAs in Crohns disease? (Stephen Hanauer, Henit Yanai, Emma Calabrese). Steroids. 17 Steroids in Crohn's disease: do the benefits outweigh the dangers? (A. Hillary Steinhart). Immunomodulators. 18 Thioguanine nucleotide measurement: Non-adherent, shunter, under-dosed or resistant? (Miles Sparrow). 19 Thiopurines and the sun: what should be done? (Conal M. Perrett, Jane M. McGregor, Catherine A. Harwood). 20 Do thiopurines worsen risk and prognosis of cervical neoplasia? (Jeremy D. Sanderson and Melissa A. Smith). 21 Optimising use of methotrexate (Anna Foley and Peter R. Gibson). 22 Which calcineurin inhibitor and when? (A. Barney Hawthorne). Biologics. 23 Are all anti-TNF agents the same? (Jennifer L. Jones). 24 One drug or two: Do patients on biologics need concurrent immunomodulation? (Glen A. Doherty and Adam S. Cheifetz). 25 How do we identify patients needing early aggressive therapy and what should we use? (Marc Ferrante and Severine Vermeire). 26 What is the role of biologics in UC? (Joanna K. Law and Brian Bressler). 27 What can we do with Crohn's patients refractory to antiTNF therapy? (David T. Rubin). 28 Which EIMs respond to biologics? (Tina A. Mehta and CS Probert). 29 Use and abuse of biologics in pregnancy (Marla C. Dubinsky). 30 Is anti-TNF therapy safe to use in people with a history of malignancy? (Mark Lust and Simon Travis). 31 What and how should we tell patients about the risks of immunomodulators and biologics? (Corey A Siegel). 32 When, how and in whom should we stop biologics? (Edouard Louis, Jacques Belaiche, Catherine Reenaers). Part 5: Other treatments. 33 Avoiding drug interactions (Tim Elliott and Peter M. Irving). 34 Is there still a role for ursodeoxycholic acid treatment in patients with inflammatory bowel disease associated with primary sclerosing cholangitis? (Emmanouil Sinakos & Keith Lindor). 35 Stem cell transplantation for Crohn's: what's the risk-benefit ratio? (Venkataraman Subramanian and Christopher J Hawkey). 36 Complementary Therapy: Is There a Needle in the Haystack? (Shane M. Devlin). Part 6: Surgical Dilemmas in IBD. 37 Optimising IBD patients for surgery and recovery (Jonathan Wilson and Alastair Windsor). 38 Is surgery the best initial treatment for limited ileocaecal Crohn's disease? (Tom Oresland). 39 Laparoscopic or open surgery for IBD? (Donna Appleton and Michael Hershman). 40 Perianal Crohn's disease - optimal management (David A. Schwartz and Norman R. Clark III). 41 Does anti-TNF therapy increase the risk of Complications of surgery? (Ming Valerie Lin, Wojciech Blonski and Gary R. Lichtenstein). 42 Pouches for Indeterminate Colitis and Crohn's Disease: Act Now, Pay Later? (Phillip Fleshner). 43 Dealing with pouchitis (Bo Shen and Simon McLaughlin). Part 7: Unsolved issues in IBD. 44 Mucosal healing in IBD - does it matter? (Geert D'Haens). 45 Vitamin D in IBD: from genetics to bone health via cancer and immunology (Helen M. Pappa and Richard J. Grand). 46 Got Milk? Medication Use and Nursing in Women with IBD (Sunanda Kane). 47 Does stress matter? (Robert Maunder). 48 IBS is common in IBD: fact or fallacy? (James Goodhand & David Rampton). 49 So where is all the cancer? (Judith E. Baars & C. Janneke van der Woude). Part 8: Nutrition in IBD. 50 What should patients with IBD eat? (Emile Richman, Keith Leiper, Jonathan Rhodes). 51 Enteral Nutrition in Crohn's - Who for, When, How and Which Formula? (R. Shamir and Ernest G. Seidman). 52 Optimizing treatment of iron deficiency anemia (Hermann Schulze and Axel Dignass). Part 9: Management process. 53 IBD Standards: will they enhance patient care? (Michael D. Kappelman). 54 Your treatment won't work if the patient doesn't take it (Rob Horne). 55 Inflammatory Bowel Disease: What to tell your ED team (Louise Langmead). 56 Transitioning from pediatric to adult care (Elizabeth J. Hait and Laurie N. Fishman). 57 Medicolegal Pitfalls in Inflammatory Bowel Disease (IBD) Care (William J. Tremaine).
Specifications
Publisher
John Wiley and Sons Ltd
Publication date
November 11, 2011
Pages
268
ISBN
9781444334548
Format
Paperback
More titles in this specialist area
O/E CURRENT Diagnosis & Treatment Gastroenterology, Hepatology, & Endoscopy
Richard BlumbergRobert BurakoffNorton J. Greenberger
Your email address has been noted. We will inform you when this item is available again.
Book condition
An important factor of a second-hand book is the condition of the book. The buyer may not be surprised. Always mention damages or defects. We use a system with 3 stars:
The book is acceptable: you have used it to study and made notes and markings – but everything is still readable. The cover and pages are in good condition.
The book still looks good: there are a few notes in it and you marked it. There are hardly any signs of use on the cover and pages
The book is (almost) new: you have not written or marked in it. There are no signs of use on the cover and pages
You need a code for this download
Your code is incorrect.
Log in
Not registered yet?
Create an account to buy or link an Acco share and buy your books and supplies at reduced rates.